Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Oncology

The Blueprint of the Tumor: Biology and Subtypes

At a Glance

Renal Cell Carcinoma (RCC) is a family of kidney cancers with different genetic drivers. Identifying your exact subtype—like clear cell, papillary, or chromophobe—is essential, as it dictates how the tumor behaves and which targeted treatments or immunotherapies will work best for you.

While you may hear the term “kidney cancer,” it is not a single disease. Renal Cell Carcinoma (RCC) is actually a family of different cancers, each with its own “genetic fingerprint” and behavior [1]. Understanding your specific subtype is critical because it tells your doctors how the tumor is likely to act and which treatments are most likely to work [2].

The Role of the VHL Gene in Clear Cell RCC

Clear Cell RCC (ccRCC) is the most common subtype, making up about 70-80% of cases [3]. The “engine” driving most clear cell tumors is a mutation in the VHL gene [4].

In a healthy body, the VHL gene acts like a brake, stopping the body from growing new blood vessels when they aren’t needed. When the VHL gene is lost or broken, the “brake” is removed, leading to a chain reaction:

  1. HIF Accumulation: Proteins called Hypoxia-Inducible Factors (HIF) build up inside the cells [5].
  2. False Alarm: These HIF proteins trick the cell into thinking it is starving for oxygen, even when oxygen is plentiful [4].
  3. Angiogenesis: The cell sends out a signal called VEGF (Vascular Endothelial Growth Factor), which orders the body to build a massive network of new blood vessels to feed the tumor [6].

Because of this specific biology, many modern treatments for ccRCC work by blocking these growth signals (VEGF) or the HIF proteins themselves [7].

Comparing the Major Subtypes

Beyond clear cell, there are “non-clear cell” subtypes. These have different genetic drivers and may not respond to the same drugs as clear cell RCC [8].

Subtype Frequency Common Driver Typical Behavior
Clear Cell (ccRCC) ~75% VHL mutation Highly vascular; responds well to VEGF and immunotherapy [3][4].
Papillary (pRCC) ~10-15% MET mutations (Type 1) Divided into Type 1 (usually slower) and Type 2 (more aggressive) [9].
Chromophobe (chRCC) ~5% Chromosome losses Generally less aggressive with a better long-term prognosis [10][11].

Rare and Aggressive Subtypes

Some types of RCC are much rarer and require specialized care from centers familiar with their unique biology:

  • Clear Cell Papillary RCC (ccpRCC): Despite the scary name, this is a very “indolent” or slow-growing subtype that rarely spreads [12].
  • Collecting Duct Carcinoma (CDC): A rare and very aggressive form that starts in the drainage system of the kidney [13].
  • Renal Medullary Carcinoma (RMC): An aggressive subtype almost exclusively found in young people with sickle cell trait or disease [14]. It is characterized by the loss of a protein called SMARCB1 [15].

Why This Matters for You

Your pathology report—the document created by a doctor who looks at your tumor cells under a microscope—will identify your subtype. Knowing if you have a VHL-driven tumor or a MET-driven tumor (like Papillary Type 1) allows your medical team to move away from “trial and error” and toward a more personalized treatment plan [16]. If you have a family history of kidney tumors, these genetic findings can also help determine if you should be tested for hereditary syndromes like Von Hippel-Lindau disease [1].

Common questions in this guide

What are the main subtypes of renal cell carcinoma?
The most common subtype is clear cell RCC, which accounts for 70 to 80 percent of cases. Other primary subtypes include papillary RCC and chromophobe RCC, each with its own distinct biology and behavior.
What is the VHL gene's role in clear cell kidney cancer?
In clear cell RCC, a mutation in the VHL gene removes the cell's natural brake on blood vessel growth. This tricks the cell into building a massive network of new blood vessels to feed the tumor, a process that many modern treatments are designed to block.
How does my RCC subtype affect my treatment options?
Your specific subtype tells your doctors how the tumor is likely to behave and which drugs will be most effective. For example, clear cell RCC often responds well to therapies that block blood vessel growth, while non-clear cell types may require different approaches.
Who should get genetic testing for kidney cancer?
Genetic testing may be recommended if your pathology report shows specific genetic markers, if you have a family history of kidney tumors, or if you are diagnosed with certain rare subtypes. This testing checks for hereditary syndromes like Von Hippel-Lindau disease.
What is renal medullary carcinoma (RMC)?
RMC is a rare and highly aggressive subtype of kidney cancer. It is almost exclusively found in young people who have sickle cell trait or sickle cell disease, and is driven by the loss of a specific protein in the tumor cells.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific histological subtype of my kidney cancer?
  2. 2.Does my pathology report show VHL gene mutations or other specific molecular markers?
  3. 3.Based on my subtype, is my cancer considered 'indolent' (slow-growing) or 'aggressive'?
  4. 4.Should I consider genetic testing for hereditary syndromes like Von Hippel-Lindau or Birt-Hogg-Dubé?
  5. 5.Are there clinical trials specifically for my non-clear cell subtype (e.g., Papillary or Chromophobe)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Hereditary syndromes and RCC: what radiologists need to know.

    Charbel C, Withey SJ, Serrao E, et al.

    Abdominal radiology (New York) 2026; (51(6)):3038-3053 doi:10.1007/s00261-025-05302-2.

    PMID: 41284030
  2. 2

    Perioperative systemic treatments in renal cell carcinoma.

    Goswamy R, Kalemoglu E, Master V, Bilen MA

    Frontiers in oncology 2024; (14()):1362172 doi:10.3389/fonc.2024.1362172.

    PMID: 38841158
  3. 3

    Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma.

    Toth AT, Cho DC

    Journal of kidney cancer and VHL 2020; (7(4)):17-26 doi:10.15586/jkcvhl.2020.156.

    PMID: 33364146
  4. 4

    Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.

    Liao C, Hu L, Zhang Q

    Nature reviews. Urology 2024; (21(11)):662-675 doi:10.1038/s41585-024-00876-w.

    PMID: 38698165
  5. 5

    THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.

    Kaelin WG

    Transactions of the American Clinical and Climatological Association 2022; (132()):170-181.

    PMID: 36196173
  6. 6

    On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.

    Cho H, Du X, Rizzi JP, et al.

    Nature 2016; (539(7627)):107-111 doi:10.1038/nature19795.

    PMID: 27595393
  7. 7

    Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.

    Wiley HE, Srinivasan R, Maranchie JK, et al.

    Ophthalmology 2024; (131(11)):1324-1332 doi:10.1016/j.ophtha.2024.05.024.

    PMID: 38849055
  8. 8

    Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.

    Vento J, Zhang T, Kapur P, et al.

    Cancers 2025; (17(9)) doi:10.3390/cancers17091527.

    PMID: 40361453
  9. 9

    Hereditary Renal Cancer Syndromes.

    Yanus GA, Kuligina ES, Imyanitov EN

    Medical sciences (Basel, Switzerland) 2024; (12(1)) doi:10.3390/medsci12010012.

    PMID: 38390862
  10. 10

    Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.

    Leibovich BC, Lohse CM, Cheville JC, et al.

    European urology 2018; (73(5)):772-780 doi:10.1016/j.eururo.2018.01.005.

    PMID: 29398265
  11. 11

    Renal tumors with different histological types occurring in the same kidney: A case report.

    Akihiro M, Udo K, Ito M, et al.

    Urology case reports 2025; (59()):102991 doi:10.1016/j.eucr.2025.102991.

    PMID: 40092398
  12. 12

    Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC).

    Rysz J, Franczyk B, Ławiński J, Gluba-Brzózka A

    International journal of molecular sciences 2021; (23(1)) doi:10.3390/ijms23010151.

    PMID: 35008576
  13. 13

    Collecting duct carcinoma with retroperitoneal mass as initial presentation: a rare case report.

    Ye R, Liao Y, Xia T, et al.

    BMC urology 2023; (23(1)):127 doi:10.1186/s12894-023-01295-6.

    PMID: 37495956
  14. 14

    Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas.

    Seo AN, Yoon G, Ro JY

    Advances in anatomic pathology 2017; (24(2)):65-77 doi:10.1097/PAP.0000000000000138.

    PMID: 28181950
  15. 15

    Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

    Ohe C, Smith SC, Sirohi D, et al.

    The American journal of surgical pathology 2018; (42(3)):279-292 doi:10.1097/PAS.0000000000001000.

    PMID: 29309300
  16. 16

    The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.

    de Joode K, van de Geer WS, van Leenders GJLH, et al.

    Scientific reports 2023; (13(1)):10720 doi:10.1038/s41598-023-37764-z.

    PMID: 37400554

This page provides educational information about renal cell carcinoma subtypes and genetics. Always discuss your specific pathology report and treatment options with your oncologist.

Get notified when new evidence is published on Renal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.